This research looks at a specific group of people who have suffered a stroke caused by a large blockage in the front part of the brain. These patients received a procedure to remove the clot, known as thrombectomy. The study team wanted to know if giving extra steroid medicine, called methylprednisolone, helped them recover better. They focused on a specific detail in the blood called the white blood cell count. This count can rise when the body is fighting infection or inflammation. The researchers found that patients with higher white blood cell counts seemed to benefit more from the steroid treatment. They also looked at whether the medicine caused any serious bleeding or other safety problems. The results showed that higher white blood cell counts were linked to lower risks of death and pneumonia. The study also found that the benefit of the steroid treatment was stronger in patients with higher white blood cell counts. This suggests the medicine might work differently depending on the body's immune response. It is important to remember that this was a secondary analysis. This means the researchers looked at data from a larger trial that was already done. They did not start this specific question at the beginning of the original study. Because of this, the findings need to be checked in new studies designed specifically for this question. The original trial involved over 1,200 patients. The analysis looked at how well patients did at 90 days. Doctors use a scale called the modified Rankin Scale to measure recovery. Patients with higher white blood cell counts had better scores on this scale. They also had fewer deaths and fewer cases of pneumonia. The study did not report any new safety concerns. There was no sign of increased bleeding in the brain or stomach. However, because this is a secondary look at old data, doctors should not change their usual treatment plans yet. The study team says more research is needed to confirm these results. Patients should talk to their doctors about their specific situation. Every stroke is different, and what works for one person may not work for another. This study adds to the growing list of information about stroke care. It helps scientists understand how the body reacts to treatment. But it does not prove that methylprednisolone is a standard cure for all stroke patients. The link between white blood cell counts and treatment success is interesting. It could help doctors decide who might benefit most from extra medicine in the future. Until more evidence is available, standard care remains the best choice for most patients.
Higher admission WBC predicts favorable methylprednisolone effect after thrombectomyHigher white blood cell counts linked to better methylprednisolone effects in stroke patients
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This study represents a secondary analysis of a randomized, placebo-controlled trial involving 1201 patients. The population consisted of individuals with anterior-circulation large-vessel occlusion stroke who achieved successful reperfusion after thrombectomy. The setting location was not reported. The primary investigation focused on the relationship between admission white blood cell counts and the estimated treatment effects of adjunctive methylprednisolone compared with placebo. The follow-up period extended for 90 days. The study design allowed for the assessment of how baseline inflammatory markers might modify the response to corticosteroid therapy in this specific stroke cohort.
The intervention involved the administration of adjunctive methylprednisolone. The comparator group received placebo. Specific dosing protocols for the methylprednisolone were not detailed in the provided data. The primary outcome measured was the 90-day modified Rankin Scale (mRS 0-6). This scale assesses disability levels ranging from no symptoms to death. Secondary outcomes included mRS 0-3, mRS 0-4, early NIHSS, mortality, symptomatic intracranial hemorrhage (sICH), any intracranial hemorrhage, pneumonia, and gastrointestinal bleeding.
Analysis of the 90-day ordinal mRS distribution revealed that results were more favorable in patients with WBC greater than or equal to 10 times 10 to the power of 6 per liter. The adjusted common odds ratio for this favorable outcome was 1.59. The 95% confidence interval for this effect size ranged from 1.11 to 2.28. The p-value for this association was not explicitly reported as a single number in the primary outcome section, but the direction was noted as favorable. Mortality was lower in patients with WBC greater than or equal to 10 times 10 to the power of 6 per liter. The adjusted odds ratio for mortality was 0.60. The 95% confidence interval for this mortality reduction ranged from 0.37 to 0.96. Pneumonia rates were also lower in this high WBC group. The adjusted odds ratio for pneumonia was 0.61. The 95% confidence interval for pneumonia ranged from 0.40 to 0.93.
A treatment by WBC interaction was assessed to determine if the effect of methylprednisolone differed by baseline WBC level. This interaction showed nominal statistical significance with a p-value of 0.04. The direction of this interaction was not reported in the provided data. Safety and tolerability findings indicated that there was no apparent increase in hemorrhage or gastrointestinal bleeding. Specific adverse event rates, serious adverse event counts, and discontinuation numbers were not reported in the source data. The study did not report specific rates for symptomatic intracranial hemorrhage or any intracranial hemorrhage as absolute numbers, only as secondary outcomes.
These results compare to prior landmark studies by suggesting that inflammatory markers may predict response to adjunctive therapy. However, the study is a post hoc secondary analysis, which warrants prospective validation. The practice relevance indicates that higher admission WBC was associated with more favorable estimated treatment effects from adjunctive methylprednisolone after thrombectomy. This association must be interpreted with caution because the study design does not establish causality. The distinction between surrogate markers and clinical outcomes remains important in this context.
Key methodological limitations include the post hoc nature of the analysis and the lack of prospective validation. Potential biases inherent in secondary analyses were not fully detailed. The study did not report funding sources or conflicts of interest. Questions remain unanswered regarding the optimal WBC threshold for treatment selection and the long-term implications of this association. The evidence is observational in nature regarding the WBC interaction, so causal language is avoided. Clinicians should consider these findings as hypothesis-generating rather than definitive proof of efficacy modification.
More on Stroke
View Original Abstract ↓
Sedative-hypnotic use associated with OR 1.29 for incident Alzheimer's Disease
Meta-analysis links sedative-hypnotic drug use to higher Alzheimer risk
Related in Neurology
From Other Specialties
